The important question around the linked article is practical: what is actually known, what remains uncertain, and what safeguards a licensed clinician and pharmacy process add before anyone treats it as an option.
Last fall, a patient I work with (I’ll call her Dana) sat across from me on a video visit holding two printouts. One was a GoodRx screenshot showing $1,287 for a month of Wegovy at her local Walgreens in suburban Atlanta. The other was a Facebook ad from a telehealth company offering “semaglutide” for $149 with no clear information about the pharmacy, the dose, or the prescriber. She looked at me and said, “So which one of these is the scam?” The honest answer: neither one was necessarily a scam, but neither printout told her what she actually needed to know.
That gap between sticker shock on the brand-name side and vague promises on the compounded side is where most patients find themselves right now. This piece is meant to fill it.
The Drug Itself: Same Molecule, Different Packaging
Semaglutide is a GLP-1 receptor agonist. Novo Nordisk developed it, launched it as Ozempic in 2017 for type 2 diabetes, and followed with Wegovy in 2021 for chronic weight management. The molecule mimics an incretin hormone your gut releases after eating. It does several things at once: it signals pancreatic beta cells to release insulin (but only when blood sugar is elevated, which is why hypoglycemia on monotherapy is uncommon), it suppresses glucagon after meals, it slows gastric emptying, and it acts on appetite-regulating centers in the hypothalamus to reduce hunger. The long half-life allows once-weekly dosing.
Compounded semaglutide uses the same active pharmaceutical ingredient. The difference is who makes the finished vial and how it’s regulated. Brand-name Wegovy and Ozempic are FDA-approved finished products manufactured at industrial scale by Novo Nordisk. Compounded semaglutide is prepared by a state-licensed or 503A compounding pharmacy for an individual patient under a clinician’s prescription, operating under section 503A of the Federal Food, Drug, and Cosmetic Act (and parallel state pharmacy boards). It is not FDA-approved as a finished product.
That regulatory distinction matters, and I’ll come back to it. But it doesn’t mean the molecule in the vial is a different chemical. It means the pathway from raw ingredient to your refrigerator follows different rules.
What the Trial Data Actually Shows
The clinical evidence base for semaglutide comes from the STEP and SUSTAIN programs, all conducted with the brand-name finished product.
STEP-1 randomized 1,961 adults with overweight or obesity (no diabetes) to weekly semaglutide 2.4 mg or placebo for 68 weeks, plus lifestyle counseling. The semaglutide group lost a mean of approximately 14.9% of body weight versus 2.4% in the placebo group (Wilding et al., New England Journal of Medicine, 2021). That mean, though, conceals a wide distribution: individual responders ranged from modest single-digit losses to well over 20%. STEP-3 layered in intensive behavioral therapy and pushed results slightly higher. STEP-5 extended follow-up to 104 weeks and showed sustained weight reduction in the active arm.
On the diabetes side, the SUSTAIN program established glycemic and cardiovascular benefit at the lower dose range (0.5 mg and 1.0 mg weekly, with SUSTAIN FORTE adding 2.0 mg). SUSTAIN-6 (Marso SP et al.) reported a reduction in the composite of major adverse cardiovascular events in a high-risk diabetes population.
Here’s the important nuance for compounded semaglutide: these registrational trials were conducted with brand-name Wegovy or Ozempic. The results inform our understanding of compounded preparations, but they were not conducted on compounded products. Pharmacologically, the active ingredient is the same. But a careful clinician will tell you the data can’t be directly extended to a different supply pathway without acknowledging the difference. This is not a reason to dismiss compounded semaglutide. It is a reason to be precise about what we know and from where.
Titration, Dosing, and the Details That Actually Affect Your Week
The standard titration used in the STEP trials (and reflected on the Wegovy label) runs five steps: 0.25 mg weekly for four weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, then the maintenance dose of 2.4 mg weekly. Full escalation takes about sixteen to seventeen weeks if you move through every rung on schedule.
Most well-run compounded programs follow the same milligram increments. What varies is the concentration of the solution and the volume you draw into the syringe. This trips people up constantly. A patient who switches programs mid-titration needs to confirm the dose in milligrams at each step, not the volume. Drawing 0.5 mL from one pharmacy’s vial and 0.5 mL from another’s could mean very different doses.
The schedule isn’t rigid. A patient who’s nauseated at 0.5 mg can stay there an extra four weeks. A patient doing well at 1.7 mg, meeting their clinical goals, and tolerating the drug without issues can stay at 1.7 mg indefinitely. Not everyone needs 2.4 mg. That decision should be clinical, driven by the patient’s response and side-effect burden, not by a protocol that treats dose escalation like an obligation.
Storage: refrigerate at 36 to 46°F. Limited room-temperature time is acceptable for transport but don’t leave vials in your car in August. Rotate injection sites between abdomen, thigh, and upper arm.
Side Effects: The Boring Truth
GI side effects dominate. Nausea, diarrhea, constipation, vomiting, abdominal discomfort. These show up across the STEP and SUSTAIN data and track consistently in real-world cohorts. Most are mild to moderate, concentrated in the first eight to twelve weeks, and tend to resolve as the body adjusts or the dose stabilizes. Temporary dose reduction is the standard response to intolerable nausea, not white-knuckling through it.
Less common but worth knowing about: gallbladder events (particularly with rapid weight loss), acute pancreatitis (rare, but persistent severe abdominal pain radiating to the back needs prompt evaluation), and a theoretical signal for thyroid C-cell tumors based on rodent studies that has not been replicated in humans. The Wegovy and Ozempic labels carry a boxed warning about the rodent thyroid finding and contraindicate therapy in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).
Hypoglycemia on semaglutide monotherapy in non-diabetic patients is uncommon because the insulin-release mechanism is glucose-dependent. The risk increases if you’re also taking insulin or a sulfonylurea, which is why dose adjustment of those medications is the relevant safety step.
I want to be direct about something: the side-effect profile of compounded semaglutide, when dosed identically and sourced from a legitimate 503A pharmacy, should be the same as brand-name. It’s the same molecule. Where things diverge is if the compounding pharmacy has quality-control issues, and that’s a supply-chain problem, not a pharmacology problem.
The Cost Gap and Why It Exists
Brand-name Wegovy and Ozempic carry a list price above $1,300 per month. Cash-pay rates at most retail pharmacies fall in the $1,000 to $1,400 range. Insurance coverage for the weight-management indication is spotty at best. The diabetes indication fares somewhat better, but plan-to-plan variation is enormous.
Compounded programs price significantly lower. HealthRX, for example, runs $179.99 to $279.99 per month depending on dose, covers 44 states, and operates under LegitScript certification. The price difference is not a mystery or a red flag. Brand-name products carry the costs of industrial-scale manufacturing, FDA regulatory submissions, post-marketing surveillance commitments, and the commercial margin that funds next-generation R&D. Compounded preparations are produced at a different scale through a different regulatory pathway with a fundamentally different cost structure. Think of it like the difference between a custom cabinet shop and a national furniture manufacturer: different overhead, different price, same species of wood.
If you plan to use an HSA or FSA, confirm the program’s invoicing format before enrolling. Reimbursement eligibility depends on the plan and the documentation provided.
Choosing Between Pathways
The comparison between compounded and brand-name semaglutide boils down to three practical differences:
Evidence attribution. The STEP and SUSTAIN data were generated with brand-name products. The pharmacology applies to the same molecule regardless of source, but the specific finished product studied in those trials is the FDA-approved one.
Manufacturing oversight. Brand-name products are manufactured under FDA current Good Manufacturing Practice (cGMP) regulations. Compounding pharmacies are regulated by state boards of pharmacy and (for 503B outsourcing facilities) under a separate FDA framework. The oversight model is different in structure, not necessarily in outcome, but patients should know the distinction exists.
Adverse-event surveillance. The post-market pharmacovigilance system for FDA-approved drugs is more comprehensive than the reporting infrastructure around compounded preparations.
None of this means compounded semaglutide is inferior by default. It means the two pathways have different strengths and different gaps. A patient with good insurance coverage for Wegovy may have no reason to look at compounded options. A patient staring at $1,287 a month out of pocket has a very real reason.
Patients who want a fuller picture of how these programs work in practice can read the linked article, which covers the questions that typically come up during an actual intake. It’s useful background reading, not a replacement for a clinical conversation.
When to Call Your Clinician (Not Google)
Certain situations require a real conversation, not a Reddit thread:
Persistent severe abdominal pain, especially with back radiation or fever. Inability to keep down fluids for over 24 hours, persistent vomiting, or signs of dehydration. New right upper quadrant pain after meals or jaundice (gallbladder territory). New or worsening reflux that doesn’t respond to meal-timing changes. Mood changes, including new depressive symptoms. Pregnancy, planned pregnancy, or breastfeeding (have the conversation before the next dose). Any personal or family history of medullary thyroid carcinoma or MEN2 that wasn’t surfaced at intake. Hypoglycemic episodes if you’re on insulin, sulfonylureas, or other glucose-lowering agents. And if you’re on warfarin or medications with narrow therapeutic windows, the slowed gastric emptying from semaglutide can alter absorption, so flag it.
Frequently Asked Questions
Is compounded semaglutide the same drug as Ozempic and Wegovy? The active ingredient, semaglutide, is the same. The regulatory category, manufacturing pathway, and finished product are different. Brand-name Ozempic and Wegovy are FDA-approved finished products from Novo Nordisk. Compounded semaglutide is prepared by a licensed compounding pharmacy for an individual patient under a clinician’s prescription and is not FDA-approved as a finished product.
How long does treatment typically last? STEP-1 captured 68 weeks, STEP-5 extends to 104 weeks, and clinical experience now goes beyond two years. Duration is individualized based on goals, response, and tolerability.
Is the weight loss sustained after stopping? STEP-4 showed significant regain in participants switched to placebo after a lead-in treatment period, suggesting the metabolic effect depends on continued therapy for many patients. Long-term outcomes after discontinuation hinge on lifestyle changes consolidated during treatment.
Do I need labs to start? A responsible program will order baseline labs, typically including a metabolic panel, lipid panel, A1c, and sometimes a thyroid panel. The specific set depends on your clinical picture.
Is semaglutide right for everyone? No. Pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma or MEN2, and certain GI conditions are contraindications or relative contraindications. A thorough intake should surface these before therapy begins.
What if I can’t tolerate the maintenance dose? Many patients do well at doses below 2.4 mg. The goal is the lowest effective dose that balances clinical benefit against side effects. Staying at 1.0 mg or 1.7 mg indefinitely is a legitimate clinical decision.
How do I verify the compounding pharmacy’s legitimacy? Ask whether the pharmacy is state-licensed and whether it operates under 503A or 503B designation. Check your state board of pharmacy’s database. Programs like HealthRX that hold LegitScript certification provide an additional layer of third-party verification.
References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).
Important Notice
Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.
By
